

DAFTAR PUSTAKA

- Abraham, B. K. & Adithan, C. 2001, Genetic Polymorphism of CYP2D6. *Indian J. Pharmacol.*, **33**, 147-169.
- Afshar, M., Rouini, M. & Ala, S. 2005, Dextromethorphan metabolic phenotyping in an Iranian population. *Eur. J. Clin. Pharmacol.*, **60**, 849-54.
- Albers, S., Elshoff, J.-P., Völker, C., Richter, A. & Läer, S. 2005, HPLC quantification of metoprolol with solid-phase extraction for the drug monitoring of pediatric patients. *Biomed. Chromatogr.*, **19**, 202-207
- Alvan, G., Bechtel, R., Iselius, L. & Gundert-Remy, U. 1990, Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations *Eur. J. Clin. Pharmacol.*, **39**, 533-537
- Anonim 1995, *Farmakope Indonesia Edisi IV*, Jakarta, Departemen Kesehatan Republik Indonesia.
- Anzenbacher, P. & Anzenbacherova, E. 2003, Cytochromes P450: Review on their Basic Principles. *Proc. Indian natn Sci Acad.*, **B69 No.6**, 883-991.
- Aqil, M., Ali, A., Ahad, A., Sultana, Y., Najmi, A. K. & Saha, N. 2007, A Validated HPLC Method for Estimation of Metoprolol in Human Plasma. *Acta Chromatographica*, **19**, 130-140.
- Arneth, B., Shams, M., Hiemke, C. & Härtte, S. 2009, Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene. *Clin. Biochem.*, **42**, 1282-1290.
- Bailliet, G., Santos, M. R., Alfaro, E. L., Dipierri, J. E., Demarchi, D. A., Carnese, F. R. & Bianchi, N. O. 2007, Allele and genotype frequencies of metabolic genes in Native Americans from Argentina and Paraguay. *Mutat. Res.*, **627**, 171-177.
- Baranowska, I., Magiera, S. & Baranowski, J. 2011, UHPLC method for the simultaneous determination of β -blockers, isoflavones and their metabolites in human urine. *J. Chromatogr. B.*, **879**, 615-626.
- Basci, N. E., Bozkurt, A., Isimer, A. & Kayaalp, S. 1994, Correlation Between the Metabolic Ratios of Debrisoquine and Metoprolol in Turkish Subjects. *Pharmacol. Toxicol.*, **15**, 62-64.

- Bernard, S., Neville, K. A., Nguyen, A. T. & Flockhart, D. A. 2006, Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. *Oncologist*, **11**, 126-35.
- Bertilsson, L. 2002, Clinical Relevance of the CYP2D6 Polymorphism for the Treatment of Psychiatric Disorders. *Int. Congr. Ser.* **1244**, 11– 20.
- Bertilsson, L., Dahl, M.-L., Dalen, P. & Al-Shurbaji, A. 2002, Molecular Genetics of CYP2D6 : Clinical Relevance with Focus on Psychotropic Drugs. *Br. J. Clin. Pharmacol.*, **53**, 111-122.
- Bock, K. W., Schrenk, D., Forster, A., Griese, E.-U., Morike, K., Brockmeier, D. & Eichelbaum, M. 1994, The Influence of Environmental and Genetic Factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in Man Using Sparteine, Caffeine, and Paracetamol as Probes. *Pharmacogenetics*, **4**.
- Boralli, V. B., Coelho, E. B., Cerqueira, P. M. & Lanchote, V. L. 2005, Stereoselective analysis of metoprolol and its metabolites in rat plasma with application to oxidative metabolism. *J. Chromatogr. B.*, **823**, 195–202.
- Borg, K. O., Carlsson, E., Hoffmann, K.-J., Jonsson, T.-E., Thorin, H. & Wallin, B. 1975, Metabolism of Metoprolol- (³H) in Man, The Dog and The Rat. *Acta pharmacol. et toxicol.*, **36**, suppl. V, 125-135.
- Bradford, L. D. 2002, CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. *Pharmacogenomics*, **3** (2), 229-243.
- Brown, K. C., Hosseinipour, M. C., Hoskins, J. M., Thirumaran, R. K., Tien, H. C., Weigel, R., Tauzie, J., Shumba, I., Lamba, J. K., Schuetz, E. G., Mcleod, H. L., Kashuba, A. D. & Corbett, A. H. 2012. Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians. *Pharmacogenomics*, **13**, 113-21.
- Cai, W. M., Chen, B., Liu, Y. X. & Chu, X. 1997, Dextromethorphan metabolic phenotyping in a Chinese population. *Zhongguo yao li xue bao = Acta pharmacologica Sinica*, **18**, 441-4.
- Cai, W. M., Chen, B. & Zhang, W. X. 2007, Frequency of CYP2D6*10 and *14 alleles and their influence on the metabolic activity of CYP2D6 in a healthy Chinese population. *Clin. Pharmacol. Ther.*, **81**, 95-8.
- Çamsari, A., Arıkan, S., Avan, C., Kaya, D., Pekdemir, H., Çiçek, D., Kiyıkım, A., Sezer, K., Akkus, N., Alkan, M. & Aydogdu, S. 2003, Metoprolol, a β -1

selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. *Heart Vessels*, **18**, 188–192.

Casner, P. R. 2005, The Effect of CYP2D6 Polymorphisms on Dextromethorphan Metabolism in Mexican Americans. *J. Clin. Pharmacol.*, **45**, 1230-1235.

Chen, B. & Cai, W. M. 2003, Influence of CYP2D6*10B genotype on pharmacokinetics of propafenone enantiomers in Chinese subjects. *Acta Pharmacol Sin*, **24**, 1277-80.

Chiu, F. C. K., Damani, L. A., Li, R. C. & Tomlinson, B. 1997, Efficient high-performance liquid chromatographic assay for the simultaneous determination of metoprolol and two main metabolites in human urine by solid-phase extraction and fluorescence detection. *J. Chromatogr. B.*, **696**, 69–74.

Dahl, M.-L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M. & Sjoqvist, F. 1995, Ultrarapid Hydroxylation of Debrisoquine in a Swedish Population. Analysis of the Molecular Genetic Basis. *J. Pharmacol. Exp. Ther.*, **274**, 516-520.

Dalen, P., Dahl, M.-L., Eichelbaum, M., Bertilsson, L. & Wilkinson, G. R. 1999, Disposition of Debrisoquine in Caucasians with Different CYP2D6-Genotype Including Those With Multiple Genes. *Pharmacogenetics*, **9**, 697-706.

Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J.-D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D. W., Steen, V. W., Wolf, C. R. & Zanger, U. M. 1996, Nomenclature for Human CYP2D6 Alleles. *Pharmacogenetics*, **6**, 193-201.

Dayar, P., Leemann, T., Marmy, A. & Rosenthaler, J. 1985, Interindividual Variation of Beta-Adrenoceptor Blocking Drugs, Plasma Concentration and Effect : Influence of Genetic Status on Behaviour of Atenolol, Bopindolol and Metoprolol. *Eur. J. Clin. Pharmacol.*, **28**, 149-153.

De Groot, M. J., Ackland, M. J., Horne, V. A., Alex, A. A. & Jones, B. C. 1999, Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6. *J. Med. Chem.*, **42**, 1515-24.

Dorado, P., Cáceres, M. C., Pozo-Guisado, E., Wong, M.-L., Licinio, J. & Llerena, A. 2005, Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use. *BioTechniques*, **39**[10Suppl], S571-S574.

- Dorado, P., Heras, N., Machín, E., Hernández, F., Teran, E. & Llerena, A. 2012, CYP2D6 genotype and dextromethorphan hydroxylation phenotype in an Ecuadorian population. *Eur. J. Clin. Pharmacol.*, **68**, 637–644.
- Ebeshi, B. U., Bolaji, O. O. & Masimirembwa, C. M. 2011, Cytochrome P450 2D6 (CYP2D6) genotype and phenotype determination in the Nigerian Populations. *Asian J. Pharm. Hea. Sci.*, **1**, 47-54.
- Eichelbaum, M., Ingelman-Sundberg, M. & Evans, W. E. 2006, Pharmacogenomics and Individualized Drug Therapy. *Annu.Rev.Med.*, **57**, 119–37.
- Estevez, F., Giusti, M., Parrillo, S. & Oxandabarat, J. 1997, Dextromethorphan O-demethylation polymorphism in the Uruguayan population. *Eur. J. Clin. Pharmacol.*, **52**, 417-8.
- Fang, J., Semple, H. A. & Song, J. 2004, Determination of metoprolol, and its four metabolites in dog plasma. *J. Chromatogr. B.*, **809**, 9–14.
- FDA 2001. Guidance for Industry Bioanalytical Method Validation. Rockville.
- Franconi, F., Brunelleschi, S., Steardo, L. & Cuomo, V. 2007, Gender differences in drug responses. *Pharmacol. Res.*, **55**, 81–95.
- Gaedigk, A., Gotschall, R. R., Forbes, N. S., Simon, S. D., Kearns, G. L. & Leeder, J. S. 1999, Optimization of Cytochrome P450 2D6 (CYP2D6) Phenotype Assignment Using a Genotyping Algorithm Based on Allele Frequency Data. *Pharmacogenetics*, **9**, 669-682.
- Gan, S. H., Ismail, R., Adnan, W. A. W. & Wan, Z. 2002, Correlation of Tramadol Pharmacokinetics and CYP2D6*10 Genotype in Malaysian Subjects. *J. Pharm. Biomed. Anal.*, **30**, 189–195.
- Godbillon, J. & Duval, M. 1984, Determination of two metoprolol metabolites in human urine by high-performance liquid chromatography *J. Chromatogr.*, **309**, 198-202.
- Goryachkina, K., Burbello, A., Boldueva, S., Babak, S., Bergman, U. & Bertilsson, L. 2008, CYP2D6 is a major determinant of metoprolol disposition and effects in hospitalized Russian patients treated for acute myocardial infarction. *Eur. J. Clin. Pharmacol.*, **64**, 1163–1173.
- Gowda, K. V., Mandal, U., Selvan, P. S., Solomon, W. D. S., Ghosh, A., Sarkar, A. K., Agarwal, S., Rao, T. N. & Pal, T. K. 2007, Liquid chromatography tandem mass spectrometry method for simultaneous determination of

metoprolol tartrate and ramipril in human plasma. *J. Chromatogr. B.* , **858**, 13–21.

Griese, E.-U., Zanger, U. M., Brudermanns, U., Gaedigk, A., Mikus, G., Morike, K., Stuvén, T. & Eichelbaum, M. 1998, Assessment of The Predictive Power of Genotype for The In-Vivo Catalytic Function of CYP2D6 in a German Population *Pharmacogenetics*, **8**, 15-26.

Hadasova, E., Franke, G., Zschiesche, M., Ceskova, E., Zelenkova, O. & Siegmund, W. 1996, Debrisoquine 4-hydroxylation and sulphamethazine N-acetylation in patients with schizophrenia and major depression. *Br. J. Clin. Pharmacol.*, **41**, 428-31.

Hakim, L. 2014, *Farmakokinetika Klinik*, Yogyakarta, Bursa Ilmu.

Hanioka, N., Kimura, S., Meyer, U. A. & Gonzalez, F. J. 1990, The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. *Am J Hum Genet*, **47**, 994-1001.

Hassan, B. A. & Yusoff, Z. B. 2011, Genetic polymorphisms in the three malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. *Asian Pac J Cancer Prev*, **12**, 185-91.

He, N., Daniel, H. I., Hajiloo, L. & Shockley, D. 1999, Dextromethorphan O-demethylation polymorphism in an African-American population. *Eur. J. Clin. Pharmacol.*, **55**, 457-9.

Heim, M. & Meyer, U. A. 1990, Genotyping of Poor Metabolisers of Debrisoquine by Allele-Specific PCR Amplification. *Lancet*, **336**, 529-532.

Hersberger, M., Marti-Jaun, J., Rentsch, K. & Hanseler, E. 2000, Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR. *Clin. Chem.*, **46**, 1072-7.

Honda, M., Nozawa, T., Igarashi, N., Inoue, H., Arakawa, R., Ogura, Y., Okabe, H., Taguchi, M. & Hashimoto, Y. 2005, Effect of CYP2D6*10 on the pharmacokinetics of R- and S-carvedilol in healthy Japanese volunteers. *Biol. Pharm. Bull.*, **28**, 1476-9.

Honda, M., Ogura, Y., Toyoda, W., Taguchi, M., Nozawa, T., Inoue, H. & Hashimoto, Y. 2006, Multiple regression analysis of pharmacogenetic

variability of carvedilol disposition in 54 healthy Japanese volunteers. *Biol. Pharm. Bull.*, **29**, 772-8.

Horai, Y., Nakano, M., Ishizaki, T., Ishikawa, K., Zhou, H.-H., Zhou, B.-J., Liao, C.-L. & Zhang, L.-M. 1989, Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects : Japanese versus mainland Chinese. *Clin. Pharmacol. Ther.*, **46**, 198-207.

Horai, Y., Taga, J., Ishizaki, T. & Ishikawa, K. 1990, Correlation among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. *Br. J. Clin. Pharmacol.*, **29**, 111-115.

ICH 2005, Q2(R1): Validation of Analytical Procedures: Text and Methodology.

Ingelman-Sundberg, M. 2001, Genetic and environmental causes for interindividual variability in drug pharmacokinetics. *Int. Congr. Ser.*, **1220**, 175–186.

Ingelman-Sundberg, M. 2004, Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. *Naunyn-Schmiedeberg's Arch Pharmacol*, **369**, 89–104.

Ingelman-Sundberg, M. 2005, Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6) : clinical consequences, evolutionary aspects and functional diversity. *The Pharmacogenomics Journal*, **5**, 6–13.

Ingelman-Sundberg, M., Sim, S. C., Gomez, A. & Rodriguez-Antona, C. 2007, Influence of cytochrome P450 polymorphisms on drug therapies : Pharmacogenetic, pharmacoepigenetic and clinical aspects. *Pharmacol. Therapeut.*, **116**, 496-526.

Ishida, S., Soyama, A., Saito, Y., Murayama, N., Saeki, M., Sai, K., Ozawa, S. & Sawada, J. 2002, Determination of CYP2D6 gene alleles by the CYP450 probe array using the Affymetrix GeneChip system: comparison with sequencing results. *Drug Metab Pharmacokinet*, **17**, 157-60.

Ismail, R., Hussein, A., Teh, L. K. & Nizam Isa, M. 2000, CYP2D6 phenotypes among Malays in Malaysia. *J. Clin. Pharm. Ther.*, **25**, 379-83.

Johansson, I., Lundqvist, E., Bertilsson, L., Dahl, M.-L., Sjoqvist, F. & Ingelman-Sundberg, M. 1993, Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. *Proc. Natl. Acad. Sci.*, **90**, 11825-11829.

- Johansson, I., Oscarson, M., Yue, Q.-Y., Bertilsson, L., Sjoqvist, F. & Ingelman-Sundberg, M. 1994, Genetic Analysis of the Chinese Cytochrome P4502D Locus : Characterization of Variant CYP2D6 Genes Present in Subjects with Diminished Capacity for Debrisoquine Hydroxylation. *Mol. Pharmacol.* , **46**, 452-459.
- Johansson, I., Yue, Q. Y., Dahl, M. L., Heim, M., Sawe, J., Bertilsson, L., Meyer, U. A., Sjoqvist, E. & Ingelman-Sundberg, M. 1991, Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine *Eur. J. Clin. Pharmacol.* , **40**, 553-556
- Katoh, Y., Uchida, S., Kawai, M., Takei, N., Mori, N., Kawakami, J., Kagawa, Y., Yamada, S., Namiki, N. & Hashimoto, H. 2010, Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. *Biol. Pharm. Bull.*, **33**, 285-8.
- KEMENKES 2011, Pedoman Interpretasi Data Klinik. Jakarta.
- Kim, E.-Y., Lee, S.-S., Jung, H.-J., Jung, H.-E., Yeo, C.-W., Shon, J.-H. & Shin, J.-G. 2010, Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. *Clin. Chim. Acta*, **411**, 2043–2048.
- Kim, J., Lim, Y. R., Han, S., Han, J. S., Chun, Y. J., Yun, C. H., Lee, C. H. & Kim, D. 2013, Functional influence of human CYP2D6 allelic variations: P34S, E418K, S486T, and R296C. *Arch. Pharm. Res.*, **36**, 1500-6.
- Kim, K., Johnson, J. A. & Derendorf, H. 2004, Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms. *J. Clin. Pharmacol.*, **44**, 1083-1105.
- Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A. & Gonzalez, F. J. 1989, The Human Debrisoquine 4-Hydroxylase (CYP2D) Locus : Sequence and Identification of the Polymorphic CYP2D6 Gene, a Related Gene, and a Pseudogene. *Am. J. Hum. Genet.*, **45**, 889-904.
- Kukin, M. L. 2002, β -Blockers in Chronic Heart Failure: Considerations for Selecting an Agent. *Mayo Clin Proc*, **77**, 1199-1206.
- Labbe, L., Sirois, C., Pilote, S., Arseneault, M., Robitaille, N. M., Turgeon, J. & Hamelin, B. A. 2000, Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. *Pharmacogenetics*, **10**, 425-438.

- Lecaillon, J.-B., Godbillon, J., Abadie, F. & Gosset, G. 1984, Determination of Metoprolol and Its α -Hydroxylated Metabolite in Human Plasma by High-Performance Liquid Chromatography. *J. Chromatogr.*, **305**, 411-417.
- Lennard, M. S. 1985, Oxidation Phenotype and the Metabolism and Action of Beta-Blockers. *Klin Wochenschr*, **63**, 285-292.
- Lennard, M. S. 1985b, Quantitative analysis of metoprolol and three of its metabolites in urine and liver microsomes by high-performance liquid chromatography *J. Chromatogr.*, **342**, 199-205.
- Li, J. & Bluth, M. H. 2011. Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. *Pharmacogenomics and Personalized Medicine*, **4**, 11-33.
- Llerena, A., Dorado, P. & Peñas-Lledó, E. M. 2009, Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. *Pharmacogenomics*, **10(1)**, 17-28.
- López, M., Guerrero, J., Jung-Cook, H. & Alonso, M. E. 2005, CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. *Eur. J. Clin. Pharmacol.*, **61**, 749-754.
- Lucker, P., Moore, G., Wieselgren, I., Olofsson, B. & Bergstrand, R. 1990, Pharmacokinetic and Pharmacodynamic Comparison of Metoprolol CR/ZOK Once Daily with Conventional Tablets Once Daily and in Divided Doses. *J. Clin. Pharmacol.*, **30**, S17-S27.
- Masimirembwa, C., Hasler, J., Bertilssons, L., Johansson, I., Ekberg, O. & Ingelman-Sundberg, M. 1996, Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. *Eur J Clin Pharmacol*, **51**, 117-122.
- Masimirembwa, C. M. & Hasler, J. A. 1997, Genetic Polymorphism of Drug Metabolising Enzymes in African Populations: Implications for the Use of Neuroleptics and Antidepressants. *Brain Res. Bull.*, **44(5)**, 561-571.
- Mcelroy, S., Richmond, J., Lira, M., Friedman, D., Silber, B. M. & Milos, P. M. 2000, CYP2D6 Genotyping as an Alternative to Phenotyping for Determination of Metabolic Status in a Clinical Trial Setting. *AAPS Pharmsci*, **2 (4)** article 33.
- Mcgill, J. B. 2010, Optimal use of β -blockers in high-risk hypertension: A guide to dosing equivalence. *Vasc. Health Risk Manag.*, **6**, 363-372.

- McGourty, J. C. & Silas, J. H. 1985, Metoprolol metabolism and debrisoquine oxidation polymorphism-population and family studies. *Br. J. Clin. Pharmacol.*, **20**, 555-566.
- Meyer, U. A. & Zanger, U. M. 1997, Molecular mechanisms of genetic polymorphisms of drug metabolism. *Annu. Rev. Pharmacol. Toxicol.*, **37**, 269-296.
- Moffat, A. C., Osselton, M. D., Widdop, B. & Watts, J. 2011, Clarke's Analysis of Drugs and Poisons in pharmaceuticals, body fluids and post mortem material. 4th Edition ed. London: Pharmaceutical Press.
- Moncrieff, J. & Simpson, D. 1989, Determination of metoprolol and its α -hydroxy metabolite in urine by direct-injection reversed-phase high-performance liquid chromatography with fluorimetric detection *J. Chromatogr.*, **488**, 498-502.
- Nebert, D. W. & Russell, D. W. 2002, Clinical importance of the cytochromes P450. *Lancet*, **360**, 1155-1162.
- Ogawa, K., Suno, M., Shimizu, K., Yoshida, M., Awaya, T., Matsubara, K. & Shiono, H. 2003, Genotyping of cytochrome p450 isoform genes is useful for forensic identification of cadaver. *Leg Med (Tokyo)*, **5**, 132-8.
- Othman, A. M., Kadi, H. O. & Thabit, A. A. M. 2014, Prevalence of CYP2D6 Phenotypes in A Yemeni Population. *World Journal of Pharmaceutical Research*, **3**, 84-91.
- Otton, S. V., Crewe, H. K., Lennard, M. S., Tucker, G. T. & Woods, H. F. 1988, Use of Quinidine Inhibition to Define the Role of the Sparteine/Debrisoquine Cytochrome P450 in Metoprolol Oxidation by Human Liver Microsomes. *J. Pharmacol. Exp. Ther.*, **247**(1), 242-247.
- Özdemir, M., Crewe, K. H., Tucker, G. T. & Rostami-Hodjegan, A. 2004, Assessment of In Vivo CYP2D6 Activity: Differential Sensitivity of Commonly Used Probes to Urine pH. *J. Clin. Pharmacol.*, **44**, 1398-1404.
- Pindurova, E., Zourkova, A., Zrustova, J., Jurica, J. & Pavelka, A. 2013. Alternative reliable method for cytochrome P450 2D6 poor metabolizers genotyping. *Mol. Biotechnol.*, **53**, 29-40
- Provan, D. & Krentz, A. 2002, Oxford Handbook of Clinical and Laboratory Investigation. New York: Oxford University Press.

- Qin, L. & Rui, W. 2006, Simultaneous analysis of tramadol, metoprolol and their metabolites in human plasma and urine by high performance liquid chromatography. *Chin. Med. J. (Engl)*. **119(23)**, 2013-2021.
- Ramesh, M. & Bharatam, P. V. 2012, CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis. *J Mol Model*, **18**, 709-20.
- Rowland, P., Blaney, F. E., Smyth, M. G., Jones, J. J., Leydon, V. R., Oxbrow, A. K., Lewis, C. J., G.Tennant, M., Modi, S., Eggleston, D. S., Chenery, R. J. & Bridges, A. M. 2006, Crystal Structure of Human Cytochrome P450 2D6. *J. Biol. Chem.*, **281**, 7614-7622.
- Shabir, G. A. 2003, Validation of high-performance liquid chromatography methods for pharmaceutical analysis Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. *J. Chromatogr. A*, **987**, 57-66.
- Shah, I. M., Breslin, C. J., Wittayanarakul, K. & Mackay, S. P. 2010, Pharmacogenetics of Cytochrome P450 2D6: A Translational Medicine Perspective *Open Conference Proc. J.*, **1**, 103-108.
- Shetty, H. U. & Nelson, W. L. 1988, Chemical Aspects of Metoprolol Metabolism. Asymmetric Synthesis and Absolute Configuration of the 3-[4-(1-Hydroxy-2-methoxyethyl)phenoxy]-1-(isopropylamino)-2-propanols, the Diastereomeric Benzylic Hydroxylation Metabolites, *J. Med. Chem.*, **31** 55-59.
- Shi, Y., Xiang, P., Li, L. & Shen, M. 2011, Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. *Forensic Sci. Int.*, **207**, 183-7.
- Shimada, S., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F. P. 1994, Interindividual Variations in Human Liver Cytochrome P-450 Enzymes Involved in the Oxidation of Drugs, Carcinogens and Toxic Chemicals : Studies with Liver Microsomes of 30 Japanese and 30 Caucasians. *J. Pharmacol. Exp. Ther.*, **270(1)**, 414-423.
- Shu, Y., Cheng, Z. N., Liu, Z. Q., Wang, L. S., Zhu, B., Huang, S. L., Ou-Yang, D. S. & Zhou, H. H. 2001, Interindividual variations in levels and activities of cytochrome P-450 in liver microsomes of Chinese subjects. *Acta Pharmacol Sin*, **22**, 283-8.

- Silas, H., Lennard, M. S., Tucker, G. T., Ramsay, L. E. & Woods, H. F. 1984, Polymorphic metabolism of α -adrenoceptor antagonists. *Br. J. clin. Pharmacol.* , **17**, 11S-19S.
- Silas, J. H., McGourty, J. C., Lennard, M. S., Tucker, G. T. & Woods, H. F. 1985, Polymorphic Metabolism of Metoprolol : Clinical Studies *Eur. J. Clin. Pharmacol.* , **28**, 85-88
- Sistonen, J., Fuselli, S., Paloa, J. U., Chauhan, N., Padh, H. & Sajantila, A. 2009, Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. *Pharmacogenet Genom*, **19**(2), 170–179.
- Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G. & Fuselli, S. 2007, CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. *Pharmacogenet Genom*, **17**, 93–101.
- Snyder, L. R., Kirkland, J. T. & Glajch, J. L. 1997, Practical HPLC Method Development, 2nd Ed. New York: John Wiley & Sons, Inc.
- Sohn, D.-R., Shin, S.-G., Park, C.-W., Kusaka, M., Chiba, K. & Ishizaki, T. 1991, Metoprolol oxidation polymorphism in a Korean population : comparison with native Japanese and Chinese populations. *Br. J. clin. Pharmacol.*, **32**, 504-507.
- Stoppelaar, F. M. D., Stolk, L. M. L., Beysens, A. J., Stappers, J. L. M. & Gorgels, A. P. M. 1999, The relative bioavailability of metoprolol following oral and rectal administration to volunteers and patients *Pharm. World Sci.* , **21**(5), 233-238.
- Takekuma, Y., Takenaka, T., Kiyokawa, M., Yamazaki, K., Okamoto, H., Kitabatake, A., Tsutsui, H. & Sugawara, M. 2007, Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis. *Biol. Pharm. Bull.*, **30**, 537-42.
- Tamminga, W. J., Wemer, J., Oosterhuis, B., Brakenhoff, J. P. G., Gerrits, M. G. F., Zeeuw, R. A. D., Leij, L. F. M. H. D. & Jonkman, J. H. G. 2001, An optimized methodology for combined phenotyping and genotyping on CYP2D6 and CYP2C19 *Eur. J. Clin. Pharmacol.*, **57**, 143-146.
- Tateishi, T. 2002, Analysis of the CYP2D6 gene in relation to its metabolic capacity in Japanese men and in comparison with other populations. *Int. Cong. Ser.*, 1244, 33–39.
- Tsuzuki, D., Hichiya, H., Okuda, Y., Yamamoto, S., Tamagake, K., Shinoda, S. & Narimatsu, S. 2003, Alteration in catalytic properties of human CYP2D6

caused by substitution of glycine-42 with arginine, lysine and glutamic acid. *Drug Metab Pharmacokinet*, **18**, 79-85.

- Ueda, M., Hirokane, G., Morita, S., Okawa, M., Watanabe, T., Akiyama, K. & Shimoda, K. 2006, The impact of CYP2D6 genotypes on the plasma concentration of paroxetine in Japanese psychiatric patients. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, **30**, 486–491.
- Veiga, M. I., Asimus, S., Ferreira, P. E., J.P.Martins, I.Cavaco, Ribeiro, V., T.N.Hai, M.G.Petzold, A.Björkman, M.Ashton & Gil, J. P. 2009, Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. *Eur. J. Clin. Pharmacol.*, **65**, 355–363.
- Venkateswarlu, P., Kumar, B. N., Sessaiah, K. & Prasad, V. V. V. 2010, Selective and sensitive method for the determination of metoprolol in human plasma using liquid chromatography coupled with tandem mass spectrometry. *Acta Pharm.*, **60**, 177–184.
- Voora, D. & Ginsburg, G. S. 2012, Clinical application of cardiovascular pharmacogenetics. *J. Am. Coll. Cardiol.*, **60**, 9-20.
- Wan, Y.-J. Y., Poland, R. E., Han, G., Konishi, T., Zheng, Y.-P., Berman, N. & Lin, K.-M. 2001, Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California. *Pharmacogenetics*, **11**, 489-499.
- Wang, G., Zhang, H., He, F. & Fang, X. 2006, Effect of the CYP2D6*10 C188T polymorphism on postoperative tramadol analgesia in a Chinese population. *Eur. J. Clin. Pharmacol.*, **62**, 927-31.
- Wanwimolruk, S., Bhawan, S., Coville, P. F. & Chalcroft, S. C. 1998, Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. *Eur. J. Clin. Pharmacol.*, **54**, 431-5.
- Weinshilboum, R. 2003. Inheritance and Drug Response. *N. Engl. J. Med*, **348** (6), 529-537.
- Yagihashi, T., Mizuno, M., Chino, B., Sato, Y., Sakuma, K., Takebayashi, T., Takao, T. & Kosaki, K. 2009, Effects of the CYP2D6*10 alleles and co-medication with CYP2D6-dependent drugs on risperidone metabolism in patients with schizophrenia. *Hum Psychopharmacol*, **24**, 301-8.
- Yasui-Furukori, N., Tomonoritateishi, Kondo, T., Mihara, K., Suzuki, A., Ono, S. & Kaneko, S. 2002, Effect of CYP2D6 genotype on pharmacokinetic interactions with psychotropic drugs. *Int. Congr. Ser.*, **1244**, 21–31.

- Yilmaz, B., Asci, A. & Arslan, S. 2010, Determination of metoprolol in human plasma and urine by high-performance liquid chromatography with fluorescence detection. *J. Sep. Sci.*, **33**, 1904–1908.
- Zanger, U. M., Raimundo, S. & Eichelbaum, M. 2004, Cytochrome P450 2D6: Overview and Update on Pharmacology, Genetics, Biochemistry. *Naunyn-Schmiedeberg's Arch Pharmacol*, **369**, 23–37.
- Zhou, S.-F. 2009, Polymorphism of Human Cytochrome P4502D6 and Its Clinical Significance. *Clin. Pharmacokinet.* , **48(11)**, 689-723.